A Case Report of Envafolimab in the Treatment of Microsatellite Stable (MSS) Metastatic Colon Cancer

Yunshan Yang; Xu Luo; Li Dai; Tong He; Siqi Luo; Yongjin Zhou; Haibin Wang; Zhiqiang Yan; Qian Wang; Xiangren Jin

doi:10.2147/OTT.S473040

A Case Report of Envafolimab in the Treatment of Microsatellite Stable (MSS) Metastatic Colon Cancer

Onco Targets Ther. 2024 Nov 25:17:1137-1144. doi: 10.2147/OTT.S473040. eCollection 2024.

Authors

Yunshan Yang^#^{1

2}, Xu Luo^#³, Li Dai^#², Tong He², Siqi Luo¹, Yongjin Zhou¹, Haibin Wang², Zhiqiang Yan², Qian Wang², Xiangren Jin²

Affiliations

¹ Clinical Medical College, Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.
² Department of Gastrointestinal Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.
³ Outpatient Department, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.

^# Contributed equally.

Abstract

Envafolimab is a novel inhibitor for programmed cell death protein-ligand 1 (PD-L1) that can be administered subcutaneously. It has been found to be effective and safe in the treatment of advanced high microsatellite unstable (MSI-H) / mismatch repair deficient (dMMR) solid tumors. Currently, the efficacy of programmed cell death protein-1 (PD-1) / programmed cell death protein-ligand 1 (PD-L1) inhibitors in the treatment of microsatellite stable (MSS) tumors is not clear. We report a case of advanced colon cancer with MSS metastases in bilateral clavicle, mediastinum, retroperitoneum, bilateral hilum, and left side of thoracic 11/12 vertebral body. After 8 months of Envafolimab treatment, there was a significant reduction in metastatic lesions. As of February 1st, 2024, the patient exhibited no significant adverse reactions. The current efficacy evaluation was the partial response (PR), and the overall survival (OS) was more than 12 months. Considering the safety and efficacy of Envafolimab observed in our case, we believe that Envafolimab may be a promising drug for the treatment of MSS metastatic colon cancer.

Keywords: Envafolimab; case report; colon cancer; immunotherapy.

Publication types

Case Reports

Grants and funding

The current work was supported by the National Natural Science Foundation of China (No.82360116) and the Guizhou Provincial Science and Technology Planning Project (Grant No. qiankehejichu-ZK [2022] general 444).